论文部分内容阅读
[目的]观察培美曲塞联合顺铂二线治疗晚期原发性肺腺癌的疗效。[方法]17例经细胞学或病理学检查确诊为Ⅲb期及Ⅳ期肺腺癌患者,给予培美曲塞500mg/m2,d1,培美曲塞给药结束30min后给予顺铂75mg/m2静滴。每3周为1个周期。[结果]17例患者CR1例,PR7例,SD5例,PD4例,疾病控制率(CR+PR+SD)76.47%(13/17),中位无进展生存期为4.1个月。不良反应主要为血液学毒性和胃肠道反应等,经过对症处理后均可耐受,无治疗相关性死亡。[结论]培美曲塞联合顺铂二线治疗晚期原发性肺腺癌疗效肯定,不良反应可耐受。
[Objective] To observe the curative effect of pemetrexed combined with cisplatin in the treatment of advanced primary lung adenocarcinoma. [Method] Seventeen patients with stage Ⅲb and Ⅳ lung adenocarcinoma diagnosed by cytology or pathology were given pemetrexed 500mg / m2, d1. Pemetrexed was administered for 30min and then given cisplatin 75mg / m2 Intravenous infusion Every 3 weeks for a period. [Results] The CR1, PR7, SD5 and PD in 17 patients were 76.47% (13/17) with disease control rate (CR + PR + SD). The median progression-free survival was 4.1 months. Adverse reactions mainly for hematological toxicity and gastrointestinal reactions, after symptomatic treatment can be tolerated, no treatment-related deaths. [Conclusion] Pemetrexed combined with cisplatin in the treatment of advanced primary lung adenocarcinoma is effective and the side effects can be tolerated.